Journal of Clinical Pediatrics ›› 2024, Vol. 42 ›› Issue (10): 868-875.doi: 10.12372/jcp.2024.24e0778
• Original Article • Previous Articles Next Articles
LONG Xiaoru(), YANG Ruling, ZHANG Zhenzhen, XU Hongmei, ZHAO Ruiqiu, ZHENG Gaihuan
Received:
2024-07-31
Published:
2024-10-15
Online:
2024-10-08
LONG Xiaoru, YANG Ruling, ZHANG Zhenzhen, XU Hongmei, ZHAO Ruiqiu, ZHENG Gaihuan. Analysis of drug resistance and clinical characteristics of children with drug-resistant tuberculosis in Chongqing[J].Journal of Clinical Pediatrics, 2024, 42(10): 868-875.
"
药物 | 耐药菌 株数 | 耐药相关突变位点 | 突变率 [n(%)] |
---|---|---|---|
异烟肼 | 37 | katG Ser315Thr | 28(75.7) |
katG Ser140Asn | 0(0.0) | ||
ahpC-54C>T | 0(0.0) | ||
fabG1-15C>T和inhA Ile194Thr | 1(2.7) | ||
fabG1-15C>T | 1(2.7) | ||
丙硫异 烟胺 | 5 | ethA Gln347* | 0(0.0) |
ethA 140_140del | 1(20.0) | ||
ethA 938_939insT | 1(20.0) | ||
fabG1-15C>T | 1(20.0) | ||
fabG1-15C>T和inhA Ile194Thr | 1(20.0) | ||
利福平 | 19 | rpoB Leu430Pro | 1(5.3) |
rpoB Asp435Ala和Leu452Pro | 1(5.3) | ||
rpoB Asp435Tyr和Asn437Asp | 2(10.5) | ||
rpoB His445Asn | 1(5.3) | ||
rpoB His445Asp | 1(5.3) | ||
rpoB His445Leu | 0(0.0) | ||
rpoB His445Tyr | 1(5.3) | ||
rpoB Ser450Leu | 10(52.6) | ||
rpoB Ser450Leu和rpoC Leu527Val | 1(5.3) | ||
利福喷丁 | 23 | rpoB Leu430Pro | 0(0.0) |
rpoB Asp435Ala和Leu452Pro | 1(4.3) | ||
rpoB Asp435Tyr和Asn437Asp | 2(8.7) | ||
rpoB His445Asn | 1(4.3) | ||
rpoB His445Asp | 1(4.3) | ||
rpoB His445Leu | 1(4.3) | ||
rpoB His445Tyr | 1(4.3) | ||
rpoB Ser450Leu | 12(52.2) | ||
rpoB Ser450Leu和rpoC Leu527Val | 1(4.3) | ||
乙胺丁醇 | 21 | embB Met306Val | 5(23.8) |
embB Met306Ile | 1(4.8) | ||
embB Met306Leu和embA -12C>T | 1(4.8) | ||
embB Ala356Val | 0(0.0) | ||
embB Ser380Asn | 0(0.0) | ||
embB Gly406Ala | 1(4.8) | ||
embB Gly406Asp | 1(4.8) | ||
embB Gly406Ser | 0(0.0) | ||
embB Gln497Arg | 1(4.8) | ||
左氧氟 沙星 | 9 | gyrA Ala90Val | 2(22.2) |
gyrA Ala90Val和Ser91Pro | 1(11.1) | ||
gyrA Asp94Gly | 5(55.6) | ||
gyrB Asn499Asp | 0(0.0) | ||
gyrB Thr500Asn | 0(0.0) | ||
gyrB Glu501Asp | 0(0.0) | ||
莫西沙星 | 12 | gyrA Ala90Val | 3(25.0) |
gyrA Ala90Val和Ser91Pro | 1(8.3) | ||
gyrA Asp94Gly | 6(50.0) | ||
gyrB Asn499Asp | 0(0.0) | ||
gyrB Thr500Asn | 0(0.0) | ||
gyrB Glu501Asp | 1(8.3) | ||
阿米卡星 | 3 | rrs 1401a>g | 3(100) |
"
项 目 | 敏感组(n=240) | 耐药组(n=51) | 统计量 | P |
---|---|---|---|---|
男性[n(%)] | 126(52.5) | 14(27.5) | χ2=10.57 | 0.001 |
年龄[n(%)] | χ2=0.37 | 0.947 | ||
0~4岁 | 75(31.2) | 18(35.3) | ||
5~9岁 | 42(17.5) | 8(15.7) | ||
10~14岁 | 105(43.8) | 21(41.2) | ||
15~18岁 | 18(7.5) | 4(7.8) | ||
民族[n(%)] | χ2=0.75 | 0.386 | ||
汉族 | 211(87.9) | 47(92.2) | ||
少数民族 | 29(12.1) | 4(7.8) | ||
居住地[n(%)] | χ2=0.07 | 0.788 | ||
城市 | 80(33.3) | 18(35.3) | ||
农村 | 160(66.7) | 33(64.7) | ||
治疗状态[n(%)] | χ2=10.85 | 0.001 | ||
初治 | 238(99.2) | 46(90.2) | ||
复治 | 2(0.8) | 5(9.8) | ||
有结核病接触史[n(%)] | 89(37.1) | 25(49.0) | χ2=2.52 | 0.113 |
有卡介苗接种史[n(%)] | 191(79.6) | 30(58.8) | χ2=9.92 | 0.002 |
有效治疗前症状持续时长[M(P25~P75)]/d | 29.1(15.9~60.0) | 18.9(10.8~46.8) | Z=0.10 | 0.923 |
住院次数[M(P25~P75)]/次 | 1.0(1.0~4.0) | 2.0(1.0~5.3) | Z=0.24 | 0.817 |
重症结核病[n(%)] | 150(62.5) | 44(86.3) | χ2=10.70 | 0.001 |
诊断[n(%)] | χ2=7.29 | 0.026 | ||
肺结核 | 119(49.5) | 16(31.4) | ||
肺外结核 | 3(1.3) | 0(0.0) | ||
肺结核合并肺外结核 | 118(49.2) | 35(68.6) | ||
治疗用药[n(%)] | χ2=48.25 | <0.001 | ||
一线药物 | 177(73.8) | 27(52.9) | ||
一线加二线药物 | 59(24.5) | 10(19.6) | ||
二线药物 | 4(1.7) | 14(27.5) | ||
治疗结局[n(%)] | χ2=6.77 | 0.009 | ||
治愈或治疗完成 | 229(95.4) | 43(84.3) | ||
治疗失败或死亡 | 11(4.6) | 8(15.7) |
"
项 目 | 敏感组(n=237) | 耐药组(n=51) | χ2值 | P |
---|---|---|---|---|
病变位置 | 7.96 | 0.019 | ||
左侧 | 37(15.6) | 2(3.9) | ||
右侧 | 70(29.5) | 11(21.6) | ||
双侧 | 130(54.9) | 38(74.5) | ||
累及肺叶数量 | 11.54 | 0.021 | ||
1叶 | 40(16.9) | 3(5.9) | ||
2叶 | 54(22.8) | 6(11.8) | ||
3叶 | 38(16.0) | 7(13.7) | ||
4叶 | 22(9.3) | 9(17.6) | ||
5叶 | 83(35.0) | 26(51.0) | ||
累及肺叶部位 | ||||
左上叶 | 151(63.7) | 36(70.6) | 0.87 | 0.351 |
左下叶 | 163(68.8) | 32(62.7) | 0.70 | 0.403 |
右上叶 | 175(73.8) | 39(76.5) | 0.15 | 0.696 |
右中叶 | 154(65.0) | 40(78.4) | 3.46 | 0.063 |
右下叶 | 157(66.2) | 42(82.4) | 5.10 | 0.024 |
病变类型 | ||||
树芽征 | 7(3.0) | 2(3.9) | 0.12 | 0.726 |
实变 | 52(21.9) | 10(19.6) | 0.14 | 0.713 |
钙化 | 56(23.6) | 10(19.6) | 0.38 | 0.535 |
坏死 | 6(2.5) | 7(13.7) | 9.20 | 0.002 |
空洞 | 45(19.0) | 7(13.7) | 0.79 | 0.376 |
肺不张 | 40(16.9) | 11(21.6) | 0.63 | 0.426 |
粟粒性病变 | 31(13.1) | 7(13.7) | 0.02 | 0.902 |
结节影 | 55(23.2) | 8(15.7) | 1.39 | 0.239 |
支气管充气征 | 22(9.3) | 9(17.6) | 3.06 | 0.080 |
支气管扩张 | 31(13.1) | 12(23.5) | 3.61 | 0.058 |
支气管狭窄 | 37(15.6) | 13(25.5) | 2.86 | 0.091 |
淋巴结病变 | 181(76.4) | 41(80.4) | 0.38 | 0.535 |
胸膜病变 | 74(21.2) | 15(29.4) | 0.07 | 0.799 |
胸腔积液 | 63(26.6) | 13(25.5) | 0.03 | 0.872 |
"
项 目 | 敏感组(n=240) | 耐药组(n=51) | χ2值 | P |
---|---|---|---|---|
抗酸染色涂片 | 5.50 | 0.019 | ||
≥1次阳性 | 68(28.3) | 23(45.1) | ||
全部阴性 | 172(71.7) | 28(54.9) | ||
TST | 7.55 | 0.056 | ||
阴性 | 87(36.2) | 27(52.9) | ||
一般阳性 | 25(10.4) | 1(2.0) | ||
中度阳性 | 39(16.3) | 5(9.8) | ||
强阳性 | 89(37.1) | 18(35.3) | ||
T-SPOT.TB阳性 | 222(92.5) | 42(82.4) | 4.40 | 0.036 |
Xpert MTB/RIF | 3.61 | 0.058 | ||
≥1次阳性 | 150(62.5) | 39(76.5) | ||
全部阴性 | 90(37.5) | 12(23.5) | ||
TB-DNA | 0.76 | 0.384 | ||
≥1次阳性 | 81(33.8) | 14(27.5) | ||
全部阴性 | 159(66.2) | 37(72.5) |
[1] | World Health Organization. Global tuberculosis report 2022 [EB/OL]. Geneva: World Health Organization, 2022 [2024-8-22]. http://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. |
[2] | Schaaf HS, Hughes J. Current treatment of drug-resistant tuberculosis in children[J]. Indian J Pediatr, 2024, 91(8): 806-816. |
[3] | Guo Q, Pan Y, Yang Z, et al. Epidemiology and clinical characteristics of pediatric drug-resistant tuberculosis in Chongqing, China[J]. PLoS One, 2016, 11(3): e0151303. |
[4] |
Zhang Y, Zhao R, Zhang Z, et al. Analysis of factors influencing multidrug-resistant tuberculosis and validation of whole-genome sequencing in children with drug-resistant tuberculosis[J]. Infect Drug Resist, 2021, 14: 4375-4393.
doi: 10.2147/IDR.S331890 pmid: 34729015 |
[5] | World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection[M/OL]. Geneva: World Health Organization, 2022. |
[6] | 赵雁林, 逄宇. 结核病实验室检验规程[M]. 北京: 人民卫生出版社, 2015. |
[7] | 张颖, 任巧丽, 赵瑞秋, 等. 儿童抗结核药物耐药比例法、微孔板法、全基因组测序检测对比研究[J]. 临床儿科杂志, 2023, 41(2): 117-124. |
[8] |
Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children[J]. Pediatr Infect Dis J, 2012, 31(4): 347-352.
doi: 10.1097/INF.0b013e318243e27b pmid: 22315002 |
[9] | Linh NN, Viney K, Gegia M, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update[J]. Eur Respir J, 2021, 58(2):2100804. |
[10] | 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288-2017)[J]. 新发传染病电子杂志, 2018, 3(1): 59-61. |
[11] | Lam C, Martinez E, Crighton T, et al. Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection[J]. Int J Infect Dis, 2021, 113 Suppl 1: S48-S54. |
[12] | Zhao J, Qian C, Jiang Y, et al. Drug-resistant characteristics, genetic diversity, and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Jiangxi, China[J]. Infect Drug Resist, 2024, 17: 2213-2223. |
[13] | Imran M. Ethionamide and prothionamide based coumarinyl-thiazole derivatives: synthesis, antitubercular activity, toxicity investigations and molecular docking studies[J]. Pharm Chem J, 2022, 56(9): 1215-1225. |
[14] | Ma P, Luo T, Ge L, et al. Compensatory effects of M. tuberculosis rpoB mutations outside the rifampicin resistance-determining region[J]. Emerg Microbes Infect, 2021, 10(1): 743-752. |
[15] | Fisher C, Patel R. Rifampin, rifapentine, and rifabutin are active against intracellular periprosthetic joint infection-associated Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 2021, 65(2):e01275-20. |
[16] |
Naz F, Ahmad N, Wahid A, et al. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis[J]. BMC Infect Dis, 2021, 21(1): 1209.
doi: 10.1186/s12879-021-06935-6 pmid: 34863099 |
[17] | Jia H, Xu Y, Sun Z. Analysis on drug-resistance-associated mutations among multidrug-resistant Mycobacterium tuberculosis isolates in China[J]. Antibiotics (Basel), 2021, 10(11): 1367. |
[18] | Chauffour A, Morel F, Reibel F, et al. A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance[J]. Clin Microbiol Infect, 2021, 27(11): 1601-1612. |
[19] | Singh PK, Singh U, Jain A. Emergence of specific gyrA mutations associated high-level fluoroquinolone-resistant Mycobacterium tuberculosis among multidrug-resistant tuberculosis cases in North India[J]. Microb Drug Resist, 2021, 27(5): 647-651. |
[20] |
Kabir S, Tahir Z, Mukhtar N, et al. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients[J]. BMC Pulm Med, 2020, 20(1): 138.
doi: 10.1186/s12890-020-1172-4 pmid: 32393213 |
[21] | Lu Z, Jiang W, Zhang J, et al. Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China[J]. PLoS One, 2019, 14(11): e0225361. |
[22] | Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis[J]. Lancet, 2018, 392(10150): 821-834. |
[23] | Islam MM, Tan Y, Hameed HMA, et al. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China[J]. J Glob Antimicrob Resist, 2020, 22: 290-295. |
[24] | 张春华, 李涛, 杜昕, 等. 2019-2021年我国4省份报告儿童肺结核病例特征分析[J]. 中华流行病学杂志, 2022, 43(11): 1739-1745. |
[25] | Li CH, Fan X, Lv SX, et al. Clinical and computed tomography features associated with multidrug-resistant pulmonary tuberculosis: a retrospective study in China[J]. Infect Drug Resist, 2023, 16: 651-659. |
[26] | Negi K, Bhaskar A, Dwivedi VP. Progressive host-directed strategies to potentiate BCG vaccination against tuberculosis[J]. Front Immunol, 2022, 13: 944183. |
[27] | Xu Y, Li Q, Zhu M, et al. The epidemiological characteristics and profile of drug-resistant tuberculosis among children with tuberculosis in Sichuan, China, 2015-2018: A retrospective study[J]. Medicine (Baltimore), 2020, 99(43): e22608. |
[28] | Song QS, Zheng CJ, Wang KP, et al. Differences in pulmonary nodular consolidation and pulmonary cavity among drug-sensitive, rifampicin-resistant and multi-drug resistant tuberculosis patients: a computerized tomography study with history length matched cases[J]. J Thorac Dis, 2022, 14(7): 2522-2531. |
[29] | 廖琼, 谭珊, 朱渝, 等. 儿童耐药结核病的临床特点及二线抗结核治疗效果分析[J]. 中华儿科杂志, 2017, 55(2): 100-103. |
[30] |
Wang Y, Sun Q, Zhang Y. Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlas[J]. J Infect, 2023, 86(5): 421-438.
doi: 10.1016/j.jinf.2023.03.020 pmid: 37003521 |
[1] | LUO Mingjing, YU Jiaming, WANG Xiaodong, ZHANG Xiaoling, YU Yue, ZHANG Yu, WEN Feiqiu, LIU Sixi. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia [J]. Journal of Clinical Pediatrics, 2025, 43(1): 21-28. |
[2] | LIU Dongxia, JIN Rong, LIN Rongjun. Risk factors analysis of severe refractory Mycoplasma pneumoniae pneumonia complicated with bronchitis obliterans in children [J]. Journal of Clinical Pediatrics, 2025, 43(1): 29-34. |
[3] | ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55. |
[4] | JIANG Weiqin, WANG Jing, CHENG Anna, CHEN Tingting, HUANG Yujuan. Predictors of recurrent febrile seizures during the same febrile illness in children with febrile seizures [J]. Journal of Clinical Pediatrics, 2025, 43(1): 8-13. |
[5] | QIU Xiu, WEI Dongmei, LIN Shanshan, XIA Huimin, ZHOU Wenhao. Principles and practice of the Born in Guangzhou Cohort Study [J]. Journal of Clinical Pediatrics, 2024, 42(9): 747-752. |
[6] | FAN Jianxia. The origins and development of the healthy life trajectory program: a cohort of community-family-mother-child multidimensional interventions for overweight and obesity in children [J]. Journal of Clinical Pediatrics, 2024, 42(9): 768-773. |
[7] | JIANG Tao, LI Shuangjie, TANG Lian, OUYANG Wenxian. Immunobiological properties of peripheral blood MAIT cells in children with chronic hepatitis B [J]. Journal of Clinical Pediatrics, 2024, 42(9): 787-790. |
[8] | ZHOU Jie, LIU Keqiang, WANG Jinling, WANG Ying. Megacystis-microcolon-intestinal hypoperistalsis syndrome caused by MYH11 elongating mutation : a case report and literatures review [J]. Journal of Clinical Pediatrics, 2024, 42(9): 798-804. |
[9] | CHU Sijia, TANG Jihong. Research progress of central nervous system injury associated with pediatric acute lymphoblastic leukemia and its treatment [J]. Journal of Clinical Pediatrics, 2024, 42(9): 811-816. |
[10] | DING Yaping, XIA Shanshan, ZHANG Chenmei. Interpretation of “2023 Children’s Renal Nutrition Working Group Clinical Practice Recommendations: Nutritional Management of Children with Acute Kidney Injury” [J]. Journal of Clinical Pediatrics, 2024, 42(8): 667-672. |
[11] | LI Yirong, LI Huiping, GAO Jingyu, XIAO Yuhua, CHEN Xiaomin, LU Yanling, ZHAO Nana, FENG Xiaoqin. Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen [J]. Journal of Clinical Pediatrics, 2024, 42(8): 673-677. |
[12] | HUANG Bo, DONG Yanying, SONG Linlan. Clinical characteristics of 348 children with infectious mononucleosis [J]. Journal of Clinical Pediatrics, 2024, 42(8): 678-683. |
[13] | WANG Dan, SHAO Jingbo, LI Hong, ZHANG Na, ZHU Jiashi, FU Pan, WANG Zhen. Clinical analysis of 38 cases of hematological malignancies complicated with tumor lysis syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 684-690. |
[14] | MA Yan, WEI Xingjiao, BAI Hua, ZHANG Yan, TIAN Xinmin, Aqsa Ahmad, LIANG Lijun. Analysis of etiological composition and clinical features of stage 5 chronic kidney disease in children in a tertiary hospital in western China [J]. Journal of Clinical Pediatrics, 2024, 42(8): 697-703. |
[15] | WANG Ye, ZHANG Linlin, CHI Zuofei, SUN Ruowen, JIANG Zehui, XU Gang. A case of clinical report of T-lymphoblastic lymphoma secondary to acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 722-727. |
|